The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients.

The molecular mechanism of anemia that is hyporesponsive to recombinant human erythropoietin (rHuEPO) in hemodialysis patients without underlying causative factors has not been investigated fully in hematopoietic stem cell system. Circulating CD34+ cells (1 x 10(4)) were isolated from rHuEPO hyporesponsive hemodialysis patients (EPO-H; n = 9), patients who were responsive to rHuEPO (EPO-R; n = 9), and healthy control subjects (n = 9). The patients with known causes of EPO hyporesponsiveness were eliminated from the current study. The cells were cultured in STEM PRO 34 liquid medium, supplemented with rHuEPO, IL-3, stem cell factor, and granulocyte-macrophage colony stimulating factor for 7 d and then transferred to a semisolid methylcellulose culture medium for performing burst forming unit-erythroid (BFU-E) colony assay. Expression of src homology domain 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1), phosphorylated Janus kinase 2 (p-JAK2), and phosphorylated signal transducer and activator of transcription 5 (p-STAT5) was assessed with Western blot analysis. In EPO-H patients, SHP-1 antisense or scrambled S-oligos were included in the culture medium, and its effects were evaluated. The number of circulating CD34+ cells was not statistically different among the three groups, and their proliferation rates were similar for 7 d in culture. However, BFU-E colonies were significantly decreased in EPO-H patients compared with EPO-R and control groups. The mRNA and protein expression of SHP-1 and p-SHP-1 was significantly increased, whereas that of p-STAT5 was reduced in EPO-H patients. The inclusion of SHP-1 antisense S-oligo in culture suppressed SHP-1 protein expression associated with p-STAT5 upregulation, increase in p-STAT5-regulated genes, and partial recovery of BFU-E colonies. In EPO-H hemodialysis patients, the EPO signaling pathway is attenuated as a result of dephosphorylation of STAT5 via upregulation of SHP-1 phosphatase activity, and SHP-1 may be a novel target molecule to sensitize EPO action in these patients.

[1]  I. Roots,et al.  Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS‐sorted peripheral blood CD4+, CD8+, CD19+, and CD56+cells , 2003, European journal of haematology.

[2]  H. Mizuguchi,et al.  Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector , 2003, Gene Therapy.

[3]  Lijun Liu,et al.  The function of the protein tyrosine phosphatase SHP-1 in cancer. , 2003, Gene.

[4]  H. Makino,et al.  Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  P. Reimer,et al.  Gene transfer in purified human hematopoietic peripheral-blood stem cells by means of electroporation without prestimulation. , 2003, The Journal of laboratory and clinical medicine.

[6]  Y. Yonemitsu,et al.  Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells , 2003, Gene Therapy.

[7]  M. Aoki,et al.  HVJ-envelope vector for gene transfer into central nervous system. , 2003, Biochemical and biophysical research communications.

[8]  Chiu-Ching Huang,et al.  Low Dose Intravenous Ascorbic Acid for Erythropoietin-Hyporesponsive Anemia in Diabetic Hemodialysis Patients with Iron Overload , 2003, Renal failure.

[9]  M. Welham,et al.  Role of the protein tyrosine phosphatase SHP-1 (Src homology phosphatase-1) in the regulation of interleukin-3-induced survival, proliferation and signalling. , 2002, The Biochemical journal.

[10]  K. Hayashi,et al.  Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. , 2002, Cancer research.

[11]  Tomoyuki Nishikawa,et al.  Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  K. Eckardt,et al.  Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  G. Stamatoyannopoulos,et al.  A High-Capacity, Capsid-Modified Hybrid Adenovirus/Adeno-Associated Virus Vector for Stable Transduction of Human Hematopoietic Cells , 2002, Journal of Virology.

[14]  M. Dolan,et al.  High Efficiency Electroporation of Human Umbilical Cord Blood CD34+ Hematopoietic Precursor Cells , 2001, Stem cells.

[15]  J. Melrose,et al.  Affinity and Western blotting reveal homologies between ovine intervertebral disc serine proteinase inhibitory proteins and bovine pancreatic trypsin inhibitor , 2001, Proteomics.

[16]  E. Ku.  Pathophysiology of renal anemia. , 2000 .

[17]  K. Eckardt.  Pathophysiology of renal anemia. , 2000, Clinical nephrology.

[18]  T. Yi,et al.  Defective expression of the SHP-1 phosphatase in polycythemia vera. , 1999, Experimental hematology.

[19]  R. Gregory,et al.  Erythropoietin receptor and STAT5-specific pathways promote SKT6 cell hemoglobinization. , 1998, Blood.

[20]  B. Julian,et al.  Angiotensin II stimulates proliferation of normal early erythroid progenitors. , 1997, The Journal of clinical investigation.

[21]  D. Wojchowski,et al.  Hematopoietic cell phosphatase negatively regulates erythropoietin-induced hemoglobinization in erythroleukemic SKT6 cells. , 1997, Blood.

[22]  A. Yoshimura,et al.  The Erythropoietin Receptor and Signal Transduction , 1996 .

[23]  Yoshimura,et al.  Physician Education: The Erythropoietin Receptor and Signal Transduction. , 1996, The oncologist.

[24]  Y. Matsuzaki,et al.  Analysis of circulating hematopoietic progenitors in patients with chronic renal failure under hemodialysis. , 1996, International journal of hematology.

[25]  T. He,et al.  Erythropoietin-induced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway , 1995, The Journal of Biological Chemistry.

[26]  R. Stocco,et al.  Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. , 1995, Genomics.

[27]  R. Foley,et al.  Cardiac function and hematocrit level. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  Ursula Klingmüller,et al.  Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals , 1995, Cell.

[29]  C. Winearls,et al.  Chairman's Workshop Report R-HuEPO hyporesponsiveness—who and why? , 1995 .

[30]  T. Drüeke.  R-HuEPO hyporesponsiveness--who and why? , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  B. Danielson.  R-HuEPO hyporesponsiveness--who and why? , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  H. Lodish,et al.  Activation and inhibition of erythropoietin receptor function: role of receptor dimerization , 1994, Molecular and cellular biology.

[33]  O. Silvennoinen,et al.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin , 1993, Cell.

[34]  P. Chrétien,et al.  A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases , 1991, Nature.